论著 Original Article

克唑替尼对ALK阳性非小细胞肺癌脑转移的疗效分析

Published at: 2016年第36卷第9期

朱礼阳 1 , 许春伟 2 , 于忠和 1
1 陆军总医院肿瘤科,北京 100700
2 军事医学科学院附属医院病理科,北京 100071
通讯作者 忠和 于 Email: 773080192@qq.com
DOI: 10.3978/j.issn.2095-6959.2016.09.010
基金:
国家自然科学基金 81372489
北京市科技计划课题 2131100006813032
军事医学科学院附属医院创新科研基金项目 ZH-2014-10

摘要

目的:非小细胞肺癌(non-small cell lung cancer,NSCLC)脑转移是影响NSCLC患者生存期及生存质量的重要因素,本研究将探讨克唑替尼在间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)阳性NSCLC脑转移患者中的疗效。方法:筛选20例ALK阳性NSCLC脑转移患者,给予克唑替尼治疗,观察临床疗效。结果:克唑替尼治疗前基线有脑转移患者,颅内疗效部分缓解(partial response,PR)12例,疾病稳定(stable disease,SD)7例,疾病进展(progressive disease,PD)1例。客观缓解率(objective response rate,ORR)为60%,疾病控制率(disease control rate,DCR)为95%。中位无进展生存期(progression free survival,PFS)为6个月(95%CI:3.92~8.08)。结论:克唑替尼治疗ALK阳性NSCLC脑转移患者有效。


Efficacy analysis of crizotinib for brain metastases in ALK positive non-small cell lung cancer

Abstract

Objective: Brain metastases have been recognized as an emerging complication in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). This study will explore the efficacy of crizotinib in ALK-positive NSCLC with brain metastases. Methods: Selected 20 cases of brain metastatic ALK positive NSCLC patients, received crizotinib therapy to clinical observation. Results: Among patients with brain metastases before treatment, 12 had partial response (PR), 7 stable disease (SD) and 1 disease progression (PD). Objective response rate (ORR) was 60%, and disease control rate (DCR) was 95%. Median progression free survival (PFS) was 6 months (95% CI: 3.92~8.08). Conclusion: Crizotinib is effective for brain metastases in ALK positive NSCLC.


comments powered by Disqus

全文

引用

引用本文: 礼阳 朱, 春伟 许, 忠和 于. 克唑替尼对ALK阳性非小细胞肺癌脑转移的疗效分析[J]. 临床与病理杂志, 2016, 36(9): 1293-1296.
Cite this article as: ZHU Liyang, XU Chunwei, YU Zhonghe . Efficacy analysis of crizotinib for brain metastases in ALK positive non-small cell lung cancer[J]. Journal of Clinical and Pathological Research, 2016, 36(9): 1293-1296.